Author

A. Mock

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 2 Approach:deep learning· 2 Research Focus:differential expression· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2

Frequent Co-Authors

A. De Falco· 1 shared A. Golebiewska· 1 shared A. Karabajakian· 1 shared A. Michelucci· 1 shared A. Muller· 1 shared A. Oudin· 1 shared A. Shnerb· 1 shared A. Skupin· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. De Falco

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Shallow nanopore RNA sequencing enables transcriptome profiling for precision cancer medicine

A. Mock, M. Braun, C. Scholl, S. Fröhling, C. Erkut

This study evaluates shallow nanopore RNA sequencing for transcriptome profiling in cancer, showing it is rapid, cost-effective, and comparable to Illumina for key analyses.

bioRxiv · May 31, 2022Cancer Biology

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

M. Prasad, J. Zorea, S. Jagadeeshan, A. Shnerb, J. Bouaoud, L. Michon, O. Novoplansky, M. Badarni, L. Cohen, K. Yagodayev, S. Tzadok, B. Rotblat, L. Brezina, A. Mock, A. Karabajakian, , M. Elkabets

This study shows that MEK1/2 inhibition temporarily improves the tumor immune microenvironment, enhancing immunotherapy effectiveness in head and neck cancer by reducing suppressive myeloid cells and boosting CD8+ T cell activity.

bioRxiv · Aug 22, 2021Cancer Biology

Primary and recurrent glioma patient-derived orthotopic xenografts (PDOX) represent relevant patient avatars for precision medicine

A. Golebiewska, A.-C. Hau, A. Oudin, D. Stieber, Y. A. Yabo, V. Baus, V. Barthelemy, E. Klein, S. Bougnaud, O. Keunen, M. Wantz, A. Michelucci, V. Neirinckx, A. Muller, T. Kaoma, , S. P. Niclou

This study shows that glioma PDOX models accurately represent patient tumors and can predict treatment responses in personalized medicine.

bioRxiv · Apr 24, 2020Cancer Biology

Integrative kinomics reveals kinase-driven subtypes of gastric adenocarcinomas with sunitinib as a potential common inhibitor

M. J. Tapken, G. M. Haag, D. Jaeger, S. Froehling, A. Mock

bioRxiv · Feb 12, 2020 · PreprintCancer Biology